CF
NGNE icon

Corebridge Financial’s Neurogene NGNE Stock Holding History

Corebridge Financial’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,826
Closed -$68.2K – 1787
2025
Q1 		$68.2K Buy
5,826
+705
+14% +$12.2K ﹤0.01% 2626
2024
Q4 		$117K Sell
5,121
-386
-7% -$14.4K ﹤0.01% 2480
2024
Q3 		$231K Sell
5,507
-34
-0.6% -$1.32K ﹤0.01% 2148
2024
Q2 		$202K Buy
+5,541
New +$195K ﹤0.01% 2187

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Corebridge Financial's NGNE Position: Q2 2025 in Review

Corebridge Financial sold out of Neurogene (NGNE) in Q2 2025, closing a stake of 5,826 shares — an estimated $68.2K sold.

Corebridge Financial first reported a position in NGNE in Q2 2024 and held it in 4 quarters. The position peaked at $231K in Q3 2024. 82 funds tracked by Wall St. Rank hold NGNE as of Q2 2025.

  • Corebridge Financial reported no remaining Neurogene position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 5,826 Neurogene shares in Q2 2025, an estimated $68.2K.
  • Corebridge Financial first reported a position in Neurogene in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Neurogene position peaked at $231K in Q3 2024.
  • 82 funds tracked by Wall St. Rank held Neurogene as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.